Overview

Location [1]
3p22.2
Pathway
Immune checkpoints
Protein [2]
Myeloid differentiation primary response protein MyD88
Synonyms [1]
MYD88D

Myeloid differentiation primary response 88 (MYD88) is a gene that encodes a cytosolic adapter protein necessary for both innate and adaptive immune response. Missense mutations, nonsense mutations, silent mutations, and in-frame deletions are observed in cancers such as leukemias, lung cancer, and skin cancer.

MYD88 is altered in 0.64% of all cancers with diffuse large B-cell lymphoma, colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations [3].

MYD88 GENIE Cases - Top Diseases

The most common alterations in MYD88 are MYD88 Mutation (0.67%), MYD88 L265P (0.16%), MYD88 Amplification (0.05%), MYD88 Loss (0.05%), and MYD88 S219C (0.02%) [3].

MYD88 GENIE Cases - Top Alterations

Significance of MYD88 in Diseases

Waldenstrom Macroglobulinemia +

Diffuse Large B-Cell Lymphoma +

Chronic Lymphocytic Leukemia +

Lymphoplasmacytic Lymphoma +

Mantle Cell Lymphoma +

Peripheral T-Cell Lymphoma +

Primary Cutaneous T Cell Non-Hodgkin Lymphoma +

Splenic Marginal Zone Lymphoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.